PatriciaABaxterMD

Pediatric Hematology & Oncology • Houston, TX

Associate Professor, Pediatric Hematology & Oncology, Baylor College of Medicine

Join to view full profile

Dr. Baxter is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Baxter's full profile

Already have an account?

Office
6621 Fannin St
Cc1410.00
Houston, TX 77030
Phone+1 832-822-4200

Education & Training

Baylor College of MedicineFellowship, Pediatric Hematology/Oncology, 2006 - 2009
Sidney Kimmel Medical College at Thomas Jefferson University/Nemours Children's Health, WilmingtonResidency, Pediatrics, 2002 - 2006
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2002

Certifications & Licensure

TX State Medical License 2008 - 2026
DE State Medical License 2005 - 2013
PA State Medical License 2002 - 2012
American Board of Pediatrics Pediatrics
American Board of Pediatrics Hospice and Palliative Medicine
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas Start of enrollment: 2012 Feb 01
Completed
Phase 1, Phase 2
Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors Start of enrollment: 2015 Jul 14
Completed
Phase 1
Panobinostat in Treating Younger Patients With Progressive Diffuse Intrinsic Pontine Glioma Start of enrollment: 2016 Apr 01
Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG Start of enrollment: 2017 Apr 04
Recruiting
Not Applicable
A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma Start of enrollment: 2018 Aug 01
Active, not recruiting
Phase 1
Roles: Principal Investigator, Study Chair, Contact
Fimepinostat in Treating Brain Tumors in Children and Young Adults Start of enrollment: 2019 Aug 07
Active, not recruiting
Early Phase 1
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion Start of enrollment: 2021 Apr 08
Recruiting
Early Phase 1
Roles: Contact
Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery Start of enrollment: 2019 Jul 25
Suspended
Phase 1, Phase 2
Roles: Contact, Principal Investigator
ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma Start of enrollment: 2022 Dec 16
Recruiting
Phase 2
Roles: Contact
Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors Start of enrollment: 2014 May 14
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
Phase I Study of APX005M in Pediatric CNS Tumors Start of enrollment: 2018 Mar 01
Active, not recruiting
Phase 1
Roles: Contact, Principal Investigator
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma Start of enrollment: 2024 Jun 15
Not yet recruiting
Phase 2
Roles: Contact, Principal Investigator
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration Start of enrollment: 2020 Jan 17
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma Start of enrollment: 2023 Apr 10
Recruiting
Phase 2
Roles: Contact
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors Start of enrollment: 2022 Nov 21
Recruiting
Phase 1, Phase 2
Roles: Contact
Targeted Pediatric High-Grade Glioma Therapy Start of enrollment: 2024 Jun 28
Not yet recruiting
Roles: Contact
Study of Ribociclib and Everolimus in HGG and DIPG Start of enrollment: 2024 Jun 28
Not yet recruiting
Phase 2
Roles: Contact
Study of Olutasidenib and Temozolomide in HGG Start of enrollment: 2024 Jun 01
Not yet recruiting
Phase 2
Roles: Contact
HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma Start of enrollment: 2022 Jul 27
Recruiting
Phase 1
Roles: Contact
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion Start of enrollment: 2024 Sep 01
Not yet recruiting
Early Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial.
Karsten Nysom, Lindsay B Kilburn, Sarah E S Leary, Daniel B Landi, Evelien de Vos-Kerkhof
Neuro-Oncology. 2024-12-19
8 citations
Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors.
Frank Y Lin, Austin Stuckert, Candise Tat, Mark White, Lucia Ruggieri
Journal of Clinical Oncology. 2024-08-10
1 citations
Fractionated radiation therapy alters energy metabolism and induces cellular quiescence exit in patient-derived orthotopic xenograft models of high-grade glioma.
Zi-Lu Huang, Zhi-Gang Liu, Qi Lin, Ya-Lan Tao, Xinzhuoyun Li
Translational Oncology. 2024-07-01

Press Mentions

New Phase 1 Clinical Trial for Pediatric CNS TumorsFebruary 24th, 2022